News
“Next Generation Vaccines for Multi-Resistant Bacteria”.
Partners: Proxi Biotech ApS, Cellvax SAS, LiteVax B.V.
“Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species”. Partners: Proxi Biotech ApS, Institut national de la Recherche agronomique (INRA), LiteVax B.V.
“Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non-Rodent Species”; Possibilities of a Single-Low-Dose Vaccine against Coronavirus Infection”
Partners: ImmunoPrecise Antibodies, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), LiteVax B.V.
“Effective and affordable flu vaccine for the globe”
LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe.
“Treatment enabled by REcombinant Advanced immunotherapy Technologies for HER2 positive tumours”.
Partners: AdaptVac, University of Copenhagen, Expres2ion, Biomedical Primate Research Centre, LiteVax.
Development of a sublingual mucosal immunization technology platform for needle-free vaccination”.
Partners: InStar Technologies a.s., Helmholtz – Zentrum für Infektionsforschung GmbH, Timeline Bioresearch AB, Chimera Biotec GmbH, LiteVax B.V.
For the third time in 2018 LiteVax visited India and joined the Dutch Trade Mission. Prime Minister Mark Rutte and four Ministers were present to support the strategic relationships and economic cooperation. During this important event LiteVax signed 3 MoU's with Indian companies for vaccine development.
One of the predecessor of LiteVax LVX adjuvant proved to be superior to Freunds’ Complete/Incomplete Adjuvant in large animal species (PMID: 27693642)
